Your browser doesn't support javascript.
loading
Matched-Pair Comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy.
Rauscher, Isabel; Krönke, Markus; König, Michael; Gafita, Andrei; Maurer, Tobias; Horn, Thomas; Schiller, Kilian; Weber, Wolfgang; Eiber, Matthias.
Afiliação
  • Rauscher I; Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany isabel.rauscher@tum.de.
  • Krönke M; Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
  • König M; Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
  • Gafita A; Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
  • Maurer T; Department of Urology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
  • Horn T; Department of Urology and Martini-Klinik, University of Hamburg-Eppendorf, Hamburg, Germany; and.
  • Schiller K; Department of Urology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
  • Weber W; Department of Radiation Oncology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
  • Eiber M; Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
J Nucl Med ; 61(1): 51-57, 2020 01.
Article em En | MEDLINE | ID: mdl-31253741
ABSTRACT
18F-labeled prostate-specific membrane antigen (PSMA)-ligand PET has several principal advantages over 68Ga-PSMA-11. The purpose of this retrospective study was to evaluate the frequency of non-tumor-related uptake and the detection efficacy comparing 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT in recurrent prostate cancer (PC) patients.

Methods:

The study included 102 patients with biochemically recurrent PC after radical prostatectomy undergoing 18F-PSMA-1007 PET/CT imaging. On the basis of various clinical variables, patients with corresponding 68Ga-PSMA-11 PET/CT scans were matched. All PET/CT scans (n = 204) were reviewed by 1 nuclear medicine physician. First, all PET-positive lesions were noted. Then, lesions suspected of being recurrent PC were differentiated from lesions attributed to a benign origin on the basis of known pitfalls and information from CT. For each region, the SUVmax of the lesion with the highest PSMA-ligand uptake was noted. Detection rates were determined, and SUVmax was compared separately for 68Ga-PSMA-11 and 18F-PSMA-1007.

Results:

In total, 18F-PSMA-1007 PET and 68Ga-PSMA-11 PET revealed 369 and 178 PSMA-ligand-positive lesions, respectively. 18F-PSMA-1007 PET revealed approximately 5 times more lesions attributed to a benign origin than did 68Ga-PSMA-11 PET (245 vs. 52 lesions, respectively). The benign lesions most frequently observed were ganglia, unspecific lymph node, and bone lesions, at a rate of 43%, 31%, and 24% for 18F-PSMA-1007 PET and 29%, 42%, and 27% for 68Ga-PSMA-11 PET, respectively. The SUVmax of lesions attributed to a benign origin was significantly higher (P < 0.0001) for 18F-PSMA-1007 PET. Further, a similar number of lesions was attributed to recurrent PC (124/369 for 18F-PSMA-1007 PET and 126/178 for 68Ga-PSMA-11 PET).

Conclusion:

The number of lesions with increased PSMA-ligand uptake attributed to a benign origin is considerably higher for 18F-PSMA-1007 PET than for 68Ga-PSMA-11 PET. This finding indicates the need for sophisticated reader training emphasizing known pitfalls and reporting within the clinical context.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oligopeptídeos / Compostos Organometálicos / Neoplasias da Próstata / Glicoproteínas de Membrana / Niacinamida / Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada / Radioisótopos de Gálio Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oligopeptídeos / Compostos Organometálicos / Neoplasias da Próstata / Glicoproteínas de Membrana / Niacinamida / Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada / Radioisótopos de Gálio Idioma: En Ano de publicação: 2020 Tipo de documento: Article